This article was originally published in Pharmaceutical Approvals Monthly
Company presented results of its pivotal Phase III study in 58 patients with Fabry disease at the American Society of Human Genetics meeting in Philadelphia Oct. 5. Twenty of 29 patients treated every two weeks for 20 weeks with intravenous agalsidase beta achieved a score of zero on a scale of 0-3 measuring the level of GL-3 in the kidney vasculature. The score indicated that patients' "blood vessels were restored to a near normal state," providing "strong evidence that the kidney should function normally as a result of treatment," the company said. Genzyme expects approval for its BLA, submitted June 23, around the end of the yea
You may also be interested in...
The US agency has revoked an umbrella emergency use authorization for infusion pumps and their accessories that it issued in mid-May.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.